Firefly Luciferase CD19 Knockout NALM6 Cell Line
Firefly Luciferase CD19 Knockout NALM6 Cell Line is a NALM6 cell line constitutively expressing Firefly (Photinus pyralis) luciferase under the control of a CMV promoter, in which CD19 (Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) has been genetically removed using CRISPR/Cas9 genome editing using a lentivirus encoding CRISPR/Cas9 gene and sgRNA (single guide RNA) targeting human CD19.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
Media Required for Cell Culture
| Name | Ordering Information |
| Thaw Medium 2 | BPS Bioscience #60184 |
| Growth Medium 2D | BPS Bioscience #79639 |
Materials Required for Cellular Assay
| Name | Ordering Information |
| ONE-Step™ Luciferase Assay System | BPS Bioscience #60690 |
| Anti-CD19 Antibody, PE-Labeled | BPS Bioscience #101625 |
| 96-well Flat Clear Bottom White Polystyrene TC-treated Microplates | Corning #3610 |
| Luminometer |
The cell line has been screened to confirm the absence of Mycoplasma species.
NALM6 is a human B cell precursor leukemia cell line derived from the peripheral blood of a patient with acute lymphoblastic leukemia. NALM6 is a unique cell line that contains features that allow for highly efficient gene targeting via homologous recombination, the process of random gene shuffling, or nucleotide cross-over. The cell line also contains a near-diploid karyotype and is easy to transfect, making NALM6 an ideal model for knock-out or knock-in studies of gene functions. The signal generated by the Firefly luciferase is proportional to cell numbers.
CD19 (also known as Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) is a glycoprotein expressed at the surface of B lymphocytes through most phases of B cell maturation. It is strictly required for B cell terminal differentiation. Mutations in the CD19 gene cause severe immune-deficiency syndromes associated with impaired antibody production, such as CVID3 (common variable immuno-deficiency 3). The majority of B cell malignancies express normal to high levels of CD19, making it a nearly ideal target for cancer immunotherapy. Blinatumomab, a CD19/CD3 bi-specific T cell engager (BiTE) has been approved for relapsed/refractory B precursor ALL (Acute lymphoblastic leukemia) and CD19 was the target of the first approved CAR-T cell therapy. Studies of CD19 function and expression profiles will continue to broaden our knowledge and support broader applications in cancer therapy.
Li Y., Zuo C., Gu L., 2021Cancer Cell Int. 21(1):623.
Adachi N., Nishijima H., Shibahara K., 2008 Biosci Trends. 2(5):169-180.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.